PROF$6.62
Chart
Performance
Key Stats
AI PROF Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralProfound Medical Corp. shows potential in its medical technology niche but faces challenges with profitability and market adoption. Current technical indicators suggest a cautious outlook.
Thematic
The company operates in the growing medical device sector, focusing on minimally invasive procedures. However, the specific application of its technology and competitive landscape warrant further investigation.
Fundamental
Profound Medical Corp. is currently unprofitable with negative earnings per share and a negative net margin. While revenue is growing, significant operating expenses are impacting the bottom line. The balance sheet shows a healthy cash position, but debt is present.
Technical
The stock price has experienced significant declines over the past year, but recent performance shows some stabilization. Technical indicators are mixed, with some suggesting oversold conditions while others indicate ongoing weakness.
| Factor | Score |
|---|---|
| Medical Technology Innovation | 70 |
| Healthcare Market Growth | 75 |
| Regulatory Approval & Adoption | 55 |
| Competitive Landscape | 60 |
| Demographic Trends | 75 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 5 |
| Growth | 65 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Debt Management | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 45 |
| Moving Averages | 50 |
| Volume | 60 |
| Support & Resistance | 70 |
| Short-term Oscillators | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Cash Position
The company has $54.91 million in cash and cash equivalents as of Q4 2024, providing a significant buffer for operations and potential investments.
Revenue Growth
The company reported a revenue of $10.68 million for the year 2024, showing an increase from the previous year's revenue of $7.199 million.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses, with a net income of -$27.816 million in 2024 and -$28.323 million in 2023, indicating a lack of profitability.
Negative Net Margin
The net margin is significantly negative across all reported periods (e.g., -260.4% in 2024), highlighting severe challenges in converting revenue into profit.
Calendar
October 2019
16
Next Dividend Date
August 2025
15
Next Earnings Date
H: $-0.34
A: $-0.40
L: $-0.47
H: 5.62M
A: 4.75M
L: 4.04M
Profile
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Seasonals
Price Target
12.10 USD
The 39 analysts offering 1 year price forecasts for PROF have a max estimate of 15.25 and a min estimate of 11.00.